A Phase 3 interventional study of 1% Clascoterone Cream and Placebo in Acne Vulgaris, sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-03-09.
Sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.
Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2026, is one of 5 in phase 3, and was the 16th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:
Pak Emirates Military Hospital · Sites in Pakistan
Ages 12–55
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Sites in China
Ages 12+
Allied Hospital Faisalabad · Sites in Pakistan
Ages 15+
Khyber Teaching Hospital
Ages 12–35
By country, each count listing its studies:
Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5 · Phase 4 7
First in 2012; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 692 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 50 across the 19 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 19 have an industry lead sponsor. The 8 most frequent:
This study is registered under Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd., one of the names counted as 3SBio Inc.. Under that name alone:
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
3SBio Inc. has 3 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
3 of the studies testing clascoterone in Acne Vulgaris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07673094Khyber Teaching HospitalComparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris | 2027-02 |
| NCT07883538Pak Emirates Military HospitalComparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgaris | 2027-04-30 |
| NCT07881315Allied Hospital FaisalabadClascoterone Versus Clindamycin Added to Adapalene/Benzoyl Peroxide for Moderate Facial Acne | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing clascoterone in Acne Vulgaris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of 1% Clascoterone Cream in the treatment of acne vulgaris.
Target population: Participants aged ≥12 years with moderate to severe acne vulgaris who meet the inclusion criteria and none of the exclusion criteria.
Treatment: The investigational group will receive 1% Clascoterone Cream, and the control group will receive placebo. Approximately 1 g of the cream will be applied evenly to the entire face twice daily (morning and evening) for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 1% Clascoterone Cream
Drug: Placebo
1% Clascoterone Cream applied topically to affected areas twice daily for the duration of the study.
Placebo cream, matching the 1% Clascoterone Cream in appearance, texture, and scent, applied topically to affected areas twice daily for the duration of the study.
P1: Proportion of participants achieving "success" at Week 12 ("success" is defined as an Investigator's Global Assessment (IGA) score of 0 or 1, with at least a 2-point reduction from baseline);
Time frame: Week 12
Proportion of participants achieving "success" at Week 4 and Week 8
Time frame: Week 4 and Week 8
Absolute change from baseline in NILC at Week 4 and Week 8
Time frame: Week 4 and Week 8
Absolute change from baseline in ILC at Week 4 and Week 8
Time frame: Week 4 and Week 8
Absolute change from baseline in total lesion count (inflammatory and non-inflammatory lesions) at Week 4, Week 8, and Week 12
Time frame: Week 4, Week 8, and Week 12
Percent change from baseline in total lesion count at Week 4, Week 8, and Week 12
Time frame: Week 4, Week 8, and Week 12
Percent change from baseline in ILC at Week 4, Week 8, and Week 12
Time frame: Week 4, Week 8, and Week 12
Percent change from baseline in NILC at Week 4, Week 8, and Week 12
Time frame: Week 4, Week 8, and Week 12
Safety: Incidence of adverse events
Time frame: Week 12
No study locations are listed for this record.
Plan to share: No — Due to the nature of the study and privacy concerns, de-identified individual participant data will not be made available to external researchers.
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Aug 2028, 27 months later.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's planned 27 months is above that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clascoterone
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. →